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Abstract
Purpose A large, randomized, double-blind, Phase III
core study demonstrated that pasireotide LAR was signif-
icantly superior to octreotide LAR at providing
GH\2.5 lg/L and normalized IGF-1 after 12 months’
treatment in patients with acromegaly. We report the effi-
cacy and safety of pasireotide LAR and octreotide LAR
after up to 26 months’ treatment.
Methods Patients with GH\2.5 lg/L and IGF-
1 B19 ULN at month 12, or patients considered to be
experiencing clinical benefit, were eligible to continue
receiving their randomized therapy in the extension. Effi-
cacy and safety in the pasireotide LAR and octreotide LAR
groups were evaluated for up to 26 months.
Results Overall, 120 patients who completed the core
study continued receiving pasireotide LAR (n = 74) or
octreotide LAR (n = 46) in the extension. At month 25,
biochemical control (GH\2.5 lg/L and normal IGF-1)
was achieved by 48.6 % (36/74) and 45.7 % (21/46) of
patients in the pasireotide LAR and octreotide LAR arms
[60.8 % (45/74) and 52.2 % (24/46) when including
patients with IGF-1\LLN], respectively. In total, 74.7 %
of pasireotide LAR and 71.6 % of octreotide LAR patients
had tumor volume decrease C20 % from baseline to month
26. Most AEs were mild or moderate. Hyperglycemia-
related AEs were seen in 62.9 and 25.0 % of pasireotide
LAR and octreotide LAR patients, respectively. No new
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safety signals were observed in the extension compared
with the core study.
Conclusions GH and IGF-1 suppression is maintained for
up to 25 months during pasireotide LAR treatment. The
safety profile of pasireotide LAR is typical of a somato-
statin analogue, except for the frequency and degree of
hyperglycemia.
Keywords Pasireotide  Octreotide  Acromegaly 
Extension
Introduction
Acromegaly is characterized by chronic hypersecretion of
growth hormone (GH), which primarily originates from a
GH-secreting pituitary adenoma and induces the synthesis
of insulin-like growth factor 1 (IGF-1). Elevated GH and
IGF-1 levels cause metabolic dysfunction and somatic
growth, resulting in significant morbidity and mortality for
patients with acromegaly. As decreasing GH to\2.5 lg/L
and IGF-1 to normal levels significantly reduces mortality
[1–4], the main treatment goal for acromegaly is to control
GH and IGF-1 levels. Additional goals are to reduce and/or
stabilize tumor size, preserve pituitary function and prevent
recurrence [5].
Long-acting somatostatin analogues are the cornerstone
of medical therapy for acromegaly and are indicated in
patients with failed surgery or as first-line treatment when
surgery is contraindicated or declined [6, 7]. Various studies
have demonstrated that somatostatin analogues can be
effective as both first- and second-line therapy over long-
term treatment [8–13]. In selected patients with active
acromegaly, long-term somatostatin analogue therapy has
been demonstrated to effectively control GH and IGF-1
levels, induce tumor volume reduction and improve hyper-
tension and cardiac performance [9, 10, 12]. However, many
patients with acromegaly do not achieve biochemical control
with the currently available somatostatin analogues [14].
Pasireotide has a broader somatostatin receptor (sst)
binding profile than the currently available somatostatin
analogues. Pasireotide has 30-, 5- and 39-fold higher
binding affinity for sst1, sst3 and sst5, respectively, than
octreotide, and a slightly lower affinity for sst2 [15]. As
demonstrated previously, pasireotide has the potential to be
an effective medical therapy for patients with acromegaly
[16, 17]. In a large, randomized, 12-month, Phase III core
study in medically naı¨ve patients with acromegaly, pa-
sireotide long-acting release (LAR) was significantly
superior (P = 0.007) to octreotide LAR at providing
GH\2.5 lg/L and normal IGF-1 [16]. Patients who
completed this core study and had GH\2.5 lg/L and IGF-
1 B19 the upper limit of normal (ULN) at month 12, or
who were considered by the investigator to be receiving
clinical benefit (irrespective of biochemical control), were
able to continue on their randomized therapy in a planned
extension study. Here we report the efficacy and safety of
pasireotide LAR and octreotide LAR after up to
26 months’ treatment in these patients.
Methods
Study design and patient population
This was a double-blind extension to a multicenter,
12-month, Phase III core study enrolling medically naı¨ve
patients with active acromegaly who either had prior
pituitary surgery or were de novo with a visible pituitary
adenoma on magnetic resonance imaging (MRI) [16]. In
the 12-month core study, patients were randomized to pa-
sireotide LAR 40 mg every 28 days (n = 176) or octreo-
tide LAR 20 mg every 28 days (n = 182) [16]. A dose
increase to pasireotide LAR 60 mg or octreotide LAR
30 mg was permitted, but not mandatory, at month 3 or 7
based on biochemical response (mean GH C2.5 lg/L and/
or IGF-1[19 ULN). Dose decreases (pasireotide LAR:
from 60 to 40 mg or from 40 to 20 mg; octreotide LAR:
from 30 to 20 mg or from 20 to 10 mg) were permitted for
tolerability, as was an increase to the original dose upon
resolution. A detailed description of the methods and
dosing employed in the core study has been published [16].
In the extension phase, patients with GH\2.5 lg/L and
IGF-1 B19 ULN at month 12, or those patients considered
by the investigator to be experiencing clinical benefit from
the study drug, were eligible to continue receiving their
randomized therapy (Fig. 1). Patients with GH C2.5 lg/L
and/or IGF-1[19 ULN could switch treatment to either
pasireotide LAR 40 mg every 28 days or octreotide LAR
20 mg every 28 days at month 13; results from these
patients are not reported here and will be described in a
separate manuscript. Patients continuing on their random-
ized therapy received the same pasireotide LAR or octre-
otide LAR dose in the extension phase that they were
receiving at the end of the core study. A dose increase was
permitted at any time during the extension when GH levels
were C2.5 lg/L and/or IGF-1[19 ULN; maximum per-
mitted doses of pasireotide LAR and octreotide LAR were
60 and 30 mg every 28 days, respectively. Dose decreases
as with the core study were permitted at any time in the
event of tolerability issues; the dose could be increased to
the original dose upon resolution.
Thirty-four patients entered the extension phase before a
protocol amendment was implemented; these patients
received unblinded pasireotide LAR treatment during the
extension. Of these patients, 15 received pasireotide LAR
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and 19 received octreotide LAR during the core study.
Prior to the protocol amendment, patients randomized to
octreotide LAR who achieved GH\2.5 lg/L and IGF-
1 B19 ULN at month 12 could not continue receiving
octreotide LAR during the extension phase; these patients
were considered to have completed the study and were
discontinued. Additionally, patients randomized to pasire-
otide LAR did not have the option to switch to octreotide
LAR at month 13 if GH was C2.5 lg/L and/or IGF-
1[19 ULN. Following the protocol amendment, patients
in both treatment arms who had GH\2.5 lg/L and IGF-
1 B19 ULN or were considered by the investigator to be
achieving drug-related clinical benefit at month 12 could
continue on their randomized therapy, and patients in both
treatment arms could switch therapies at month 13. Patients
who entered the extension phase after the protocol
amendment was implemented received treatment in a
double-blind manner up to month 26. Nineteen patients in
the pasireotide LAR arm and 13 patients in the octreotide
LAR arm completed the core study prior to the protocol
amendment but did not enter the extension phase. Based on
manual review of the response status for these patients at
month 12, it is estimated that four patients in the octreotide
LAR arm would have potentially been eligible to continue
receiving octreotide LAR during the extension phase had
they reached the end of the core study after the protocol
amendment was implemented; 14 patients in the pasireo-
tide LAR arm would have potentially been eligible to cross
over to octreotide LAR treatment during the extension
phase.
The study was conducted in accordance with the Dec-
laration of Helsinki, and an independent ethics committee
or institutional review board for each study site approved
the study protocol. All patients provided written informed
consent to participate in the trial. The ClinicalTrials.gov
identifier is NCT00600886.
Endpoints and assessments
The key efficacy endpoint assessed was the proportion of
patients who achieved biochemical control, defined as
GH\2.5 lg/L (mean GH concentration of a five-point
profile within a 2-hour time period) and normal IGF-1
(according to age and sex), at the end of the blinded
extension phase. Additional efficacy endpoints were the
proportion of patients achieving GH\2.5 lg/L and IGF-
1 B19 ULN (i.e. including patients who had IGF-1 levels
below the lower limit of normal [LLN]), the proportion
achieving GH\2.5 lg/L, the proportion achieving normal
IGF-1, and overall changes in GH and IGF-1 levels. All
GH and IGF-1 samples were measured using validated
chemiluminescent immunometric assays [Immulite
2000/1000; Diagnostic Products Corp (Siemens), Los
Angeles, CA; GH International Reference Preparation
(IRP) WHO NIBSC 2nd IS 98/574; IGF-1 IRP WHO
NIBSC 1st IRR 87/518]. The lower limit of detection for
GH was 0.1 lg/L, with intra- and inter-assay coefficients of
variation B6.6 %. For IGF-1, the lower limit of detection
was 20 lg/L, with intra- and inter-assay coefficients of
variation B6.7 %. IGF-1 values were compared with age-
and sex-standardized normal values. All samples except for
those from China were analyzed using the Immulite 2000
assay by Quest Diagnostics Nichols Institute Laboratory,
San Juan Capistrano, California, USA between March 2008
and March 2010, then by Quest Diagnostics Clinical Trials
Laboratory, Valencia, California, USA from March 2010
Fig. 1 Study design
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onwards. Samples from China were analyzed using the
Immulite 1000 assay by Kingmed Diagnostics, Guangzhou,
China. Subsequent to receiving a notification from Siemens
regarding the Immulite IGF-1 assay, Quest Diagnostics
reviewed all quality control data collected from the three
laboratories and verified that all IGF-1 data are valid.
Tumor volume was evaluated every 6 months by gad-
olinium-enhanced pituitary MRI performed by a central
reader blinded to treatment. A pituitary tumor volume
change of C20 % from screening was considered signifi-
cant. Tumor volume was calculated by hand-drawing
around the tumor circumference in coronal cross-sections,
multiplying the area by slice thickness, and summing the
resulting volumes across all slices containing tumor. As the
last assessment of GH, IGF-1 and tumor volume prior to
the end of the planned blinded extension phase was per-
formed at month 25, these data are reported up to month
25. Changes in five signs and symptoms of acromegaly
(headache, fatigue, perspiration, paresthesia and osteo-
arthralgia) were evaluated monthly and scored from 0 (no
symptom) to 4 (very severe); data are presented up to
month 26. See the Supplementary Appendix for further
details.
Safety was assessed based on the monitoring and
recording of all adverse events (AEs), evaluated according
to the National Cancer Institute Common Terminology
Criteria for AEs version 3.0 [18], as well as regular mon-
itoring of hematology, blood chemistry and urinalysis
parameters, performance of physical examinations and
electrocardiograms, and body weight measurements. Blood
samples for laboratory tests, including blood glucose
measurements, were drawn at each visit under fasted
conditions before the morning dose of study drug. Safety
data are presented for all patients in the core study (i.e. up
to month 12) and all patients who continued on their ran-
domized therapy in the extension phase (i.e. months
12–26). Extension-phase data from patients who switched
treatments at the end of the core study are not included and
will be published separately.
Statistical analyses
This analysis focuses on data from patients who continued
on their randomized therapy in the extension phase. If\3
GH samples were taken for the assessment of mean GH
(based on a five-point 2-hour profile), the value was con-
sidered to be missing at the corresponding visit. If GH and
IGF-1 assessments were taken [35 days after the pasire-
otide LAR or octreotide LAR injection, these values were
also considered to be missing at the corresponding visit.
The calculation of the proportion of patients who achieved
GH\2.5 lg/L and normal IGF-1 during the extension
phase was performed without the imputation of missing
values. Patients who discontinued treatment were consid-
ered to be non-responders at later time points. If one of the
two biochemical values (mean GH or IGF-1) was missing,
and if the available value did not meet the response criteria
for the given parameter, the patient was considered to be a
non-responder at that visit; if the available value met the
response criteria set for the given biochemical parameter,
the patient’s response status was considered missing.
Descriptive statistics for quantitative variables (i.e. GH,
IGF-1, tumor volume, signs and symptoms scores) were
based on available measurements. No formal statistical
analyses were planned to compare the pasireotide LAR and
octreotide LAR treatment arms during the extension phase.
In addition, the extension phase was not powered to
determine a difference in efficacy or safety outcomes
between the two treatment arms. For the purposes of this
analysis, changes in patient diabetic status were calculated
according to current American Diabetes Association
(ADA) criteria for normal glucose tolerance [glycated
hemoglobin (HbA1c)\5.7 %], pre-diabetes (HbA1c C5.7 to
\6.5 %) and diabetes (HbA1c C6.5 %).
Results
Patient population
In total, 141/176 (80.1 %) and 156/182 (85.7 %) patients in
the pasireotide LAR and octreotide LAR arms, respec-
tively, completed the 12-month core study. Of those
patients who completed the core study, 74 pasireotide LAR
patients and 46 octreotide LAR patients continued on their
randomized therapy in the extension phase (Table 1;
Fig. 2). The mean duration of exposure to study treatment
was 527 days (1.4 years) in the pasireotide LAR arm and
415 days (1.1 years) in the octreotide LAR arm.
Effect of treatment on GH and IGF-1 levels
Of the patients who continued receiving their randomized
treatment in the extension phase, 53/74 (71.6 %) in the pa-
sireotide LAR arm and 26/46 (56.5 %) in the octreotide LAR
arm had GH\2.5 lg/L and IGF-1 B19 ULN at entry into
the extension phase. The remainder were judged by the
investigator to have been receiving clinical benefit from
treatment. Of these patients, seven in the pasireotide LAR arm
and 11 in the octreotide LAR arm were partial responders
(defined as GH\5 lg/L and IGF-1 B1.39 ULN, but not
biochemical control), while 13 and eight patients, respec-
tively, were non-responders (defined as neither a responder
nor a partial responder), at entry into the extension phase. This
information was missing from one patient in each group.
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At month 25, 36/74 (48.6 %) pasireotide LAR and 21/46
(45.7 %) octreotide LAR patients had biochemical control
(GH\2.5 lg/L and normal IGF-1), while 45/74 (60.8 %)
and 24/46 (52.2 %) had mean GH\2.5 lg/L and IGF-
1 B19 ULN (Table 2). The proportion of patients with a
reduction in mean GH to \2.5 lg/L at the end of the
extension phase was 70.3 % (n = 52/74) for the pasireo-
tide LAR and 80.4 % (n = 37/46) for the octreotide LAR
arms (Table 2). Overall, 51.4 % (38/74) and 47.8 % (22/
46) of patients in the pasireotide LAR and octreotide LAR
arms, respectively, had normal IGF-1 at the end of the
extension (Table 2). Median GH levels were\2.5 lg/L by
month 3 in the pasireotide LAR arm and by month 6 in the
octreotide LAR arm and remained below this threshold up
to month 25. Median IGF-1 levels were within the normal
range by month 6 in the pasireotide LAR arm and month 16
in the octreotide LAR arm and remained so at month 25
(Fig. 3).
Tumor response
The mean decrease from core baseline to the end of the
blinded extension phase was 600 ± 735 mm3 (51.8 %
decrease) and 1,120 ± 2,541 mm3 (55.0 % decrease) in
the pasireotide LAR and octreotide LAR arms, respec-
tively. The proportion of patients who achieved a signifi-
cant reduction in tumor volume of C20 % at the end of the
blinded extension phase was similar in both treatment
groups (74.7 % for pasireotide LAR and 71.6 % for
octreotide LAR); the median time to significant tumor
volume reduction was 25.0 weeks for pasireotide LAR and
24.3 weeks for octreotide LAR.
Effect on signs and symptoms of acromegaly
The five assessed symptoms of acromegaly improved from
core baseline in both treatment groups. By month 26,
decreases in mean symptom scores from core baseline were
seen in the pasireotide LAR and octreotide LAR arms for
headache (0.0 ± 0.9 and 0.2 ± 0.9), fatigue (0.4 ± 1.4
and 0.4 ± 1.4), perspiration (0.0 ± 0.7 and 1.0 ± 1.2),
osteoarthralgia (0.3 ± 1.2 and 0.2 ± 1.3), and paresthesia
(0.2 ± 0.6 and 0.3 ± 0.8).
Safety and tolerability during core and extension
Overall, 23/74 (31.1 %) and 10/46 (21.7 %) patients in the
pasireotide LAR and octreotide LAR arms who continued
receiving their randomized treatment in the extension
phase discontinued treatment between months 12 and 26.
Of these, 11/23 (47.8 %) patients in the pasireotide LAR
arm and 3/10 (30.0 %) patients in the octreotide LAR arm
had GH\2.5 lg/L and IGF-1 B19 ULN at last assess-
ment. The most common reason for discontinuation during
the blinded extension phase was consent withdrawal (12.2
and 4.3 % in the pasireotide LAR and octreotide LAR
Fig. 2 Flowchart showing the number of patients who were
randomized, completed the 12-month core study and entered the
extension phase
Table 1 Patient demographics and characteristics at core baseline for
patients who continued on their randomized therapy in the extension
phase




Age, years n = 74 n = 46
Median (range) 46.5 (22 - 71) 45.0 (24 - 70)
Sex, n (%)
Female 38 (51.4) 26 (56.5)
Male 36 (48.6) 20 (43.5)
Race, n (%)
Caucasian 41 (55.4) 28 (60.9)
Black 0 1 (2.2)
Asian 21 (28.4) 9 (19.6)
Native American 3 (4.1) 0
Other 9 (12.2) 8 (17.4)
Previous surgery, n (%) 37 (50.0) 20 (43.5)
GH level, lg/L n = 70 n = 45
Mean (SD) 14.4 (21.4) 11.3 (12.7)
Median (range) 6.9 (0.8–114.6) 6.5 (1.4–64.1)
IGF-1 level, 9 ULN n = 74 n = 46
Mean (SD) 2.6 (1.2) 2.5 (1.1)
Median (range) 2.4 (0.9–5.9) 2.4 (0.9–6.5)
Tumor volume, mm3 n = 71 n = 43
Mean (SD) 1,981 (4,515) 2,429 (4,936)
Median (range) 646 (0–35,095) 772 (53–25,473)
Pituitary (2015) 18:385–394 389
123
arms, respectively); review of these cases revealed that the
majority of patients who withdrew consent did so because
they elected to undergo pituitary surgery. During the
blinded extension phase, two (2.7 %) patients in the pa-
sireotide LAR arm and one (2.2 %) patient in the octreo-
tide LAR arm discontinued because of AEs; one of these
patients, who was receiving pasireotide LAR, discontinued
because of a serious AE. Two deaths occurred during the
extension phase (major depression leading to suicide in a
pasireotide LAR patient, sepsis in an octreotide LAR
patient). Neither of the deaths were considered by the
investigator to be related to study drug.
Most patients experienced at least one AE with a sus-
pected relationship to study drug during the 26-month
study period (86.5 and 77.2 % in the pasireotide LAR and
octreotide LAR arms, respectively); most were mild to
moderate in nature. The most common AEs were diarrhea
and cholelithiasis (Table 3). Overall, 112 patients (62.9 %)
in the pasireotide LAR arm experienced a hyperglycemia-
related AE (all terms relating to elevations in blood glu-
cose, e.g. hyperglycemia, diabetes mellitus, etc.), compared
with 45 patients (25.0 %) in the octreotide LAR arm. In
total, 32 (18.0 %) and 27 (15.0 %) patients experienced at
least one serious AE in the pasireotide LAR and octreotide
LAR arms, respectively; 11 (6.2 %) and 11 (6.1 %)
patients experienced at least one serious drug-related AE.
Mean glucose and HbA1c increased in the first 3 months
after initiation of pasireotide therapy and remained stable
to 26 months (Fig. 4). For octreotide, a smaller and more
gradual increase in mean glucose and HbA1c was observed,
which peaked at months 9–12 and remained relatively
Table 2 Biochemical response
rates
Patients who discontinued
treatment during the extension
phase were considered to be
non-responders at subsequent
time points
Pasireotide LAR (n = 74) Octreotide LAR (n = 46)
n/N (%) 95 % CI n/N (%) 95 % CI
GH\2.5 lg/L and IGF-1 normalization
Month 12 46/74 (62.2) 50.1, 73.2 24/46 (52.2) 36.9, 67.1
Month 19 34/74 (45.9) 34.3, 57.9 21/46 (45.7) 30.9, 61.0
Month 25 36/74 (48.6) 36.9, 60.6 21/46 (45.7) 30.9, 61.0
GH\2.5 lg/L and IGF-1 B19 ULN
Month 12 53/74 (71.6) 59.9, 81.5 26/46 (56.5) 41.1, 71.1
Month 19 44/74 (59.5) 47.4, 70.7 23/46 (50.0) 34.9, 65.1
Month 25 45/74 (60.8) 48.8, 72.0 24/46 (52.2) 36.9, 67.1
GH\2.5 lg/L
Month 12 58/74 (78.4) 67.3, 87.1 37/46 (80.4) 66.1, 90.6
Month 19 54/74 (73.0) 61.4, 82.6 33/46 (71.7) 56.5, 84.0
Month 25 52/74 (70.3) 58.5, 80.3 37/46 (80.4) 66.1, 90.6
IGF-1 normalization
Month 12 55/74 (74.3) 62.8, 83.8 26/46 (56.5) 41.1, 71.1
Month 19 37/74 (50.0) 38.1, 61.9 24/46 (52.2) 36.9, 67.1
Month 25 38/74 (51.4) 39.4, 63.1 22/46 (47.8) 32.9, 63.1
Fig. 3 Median a GH and b IGF-1 levels during treatment. The total
numbers of patients with evaluable measurements for GH and IGF-1 are
shown beneath each graph. Oct octreotide LAR; Pas pasireotide LAR
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stable up to month 26. Of the 119 patients in the pasireotide
LAR arm with normal fasting glucose (\100 mg/dL) at
core baseline, 83 (69.7 %) experienced worsening of fast-
ing glucose levels at last available assessment during the
core or extension; 23/51 (45.1 %) patients who had core
baseline levels of 100 to\126 mg/dL had levels C126 mg/
dL at the last available assessment (Table 4). In the
octreotide LAR arm, 43/109 (39.4 %) patients with normal
baseline fasting glucose levels and 7/54 (13.0 %) patients
with baseline levels of 100 to \126 mg/dL had worse
levels at the last available assessment.
At baseline, 41.6 % (74/178) of patients in the pasire-
otide LAR arm had normal HbA1c levels; 52.7 % (39/74)
and 23.0 % (17/74) of these patients had last available
HbA1c levels in the pre-diabetic and diabetic ranges,
respectively (Table 5). Overall, 58.4 % (104/178) of
patients in the pasireotide LAR arm had a last available
HbA1c level indicating a worse diabetic status than at core
baseline. Sixty-six patients in the octreotide LAR arm had
normal HbA1c levels at baseline. Of these patients, 32
(48.5 %) and two (3.0 %) had last available HbA1c levels
in the pre-diabetic and diabetic ranges, respectively.
Overall, 28.3 % (51/180) of patients in the octreotide LAR
arm had a last available HbA1c level indicating a worse
diabetic status than at core baseline.
In total, 85 (47.8 %) pasireotide LAR patients and 48
(26.7 %) octreotide LAR patients received concomitant
anti-diabetic medication during the 26-month study period;
metformin was most commonly used. Of the patients who
were not receiving anti-diabetic medication at core base-
line, at least one anti-diabetic medication was initiated in
40.4 % (63/156) of patients in the pasireotide LAR arm and
5.7 % (8/140) of patients in the octreotide LAR arm.
Discussion
This report from the extension phase of a large Phase III
study is the first long-term analysis of pasireotide LAR in
medically naı¨ve patients (42 % post-surgical and 58 % de
novo at core baseline) with acromegaly. It demonstrates
that GH and IGF-1 suppression is maintained in patients
who continue receiving pasireotide LAR and octreotide
LAR for up to 25 months and that long-term treatment is
generally well tolerated. Importantly, median GH levels
were\2.5 lg/L and IGF-1 levels were maintained below
the ULN for up to 25 months in both treatment arms. In
addition to effects on GH and IGF-1, both pasireotide LAR
and octreotide LAR provided overall clinical benefit by
effectively improving the signs and symptoms of acro-
megaly and reducing tumor volume. These results are in
line with those of previous long-term studies of somato-
statin analogues in acromegaly [8–13]; however, few have
evaluated a combined clinical endpoint of both
GH\2.5 lg/L and normalization of IGF-1.
Patients were eligible to enter the extension study if they
had achieved biochemical control in the 12-month core
Table 3 Most common AEs ([10 % in either treatment arm)














n (%) n (%) n (%) n (%)
Diarrhea 71 (39.9) 1 (0.6) 81 (45.0) 5 (2.8)
Hyperglycemia 55 (30.9) 6 (3.4) 18 (10.0) 1 (0.6)
Cholelithiasis 54 (30.3) 2 (1.1) 71 (39.4) 3 (1.7)
Headache 40 (22.5) 2 (1.1) 49 (27.2) 5 (2.8)
Diabetes mellitus 38 (21.3) 9 (5.1) 8 (4.4) 0
Alopecia 34 (19.1) 0 36 (20.0) 0
Abdominal pain 33 (18.5) 1 (0.6) 44 (24.4) 0
Nasopharyngitis 31 (17.4) 0 29 (16.1) 0
Nausea 27 (15.2) 1 (0.6) 41 (22.8) 0
Increased blood creatine
phosphokinase
25 (14.0) 6 (3.4) 24 (13.3) 4 (2.2)
Arthralgia 21 (11.8) 1 (0.6) 25 (13.9) 1 (0.6)
Back pain 21 (11.8) 0 22 (12.2) 2 (1.1)
Abdominal distension 21 (11.8) 1 (0.6) 22 (12.2) 1 (0.6)
Dizziness 21 (11.8) 0 20 (11.1) 0
Fatigue 19 (10.7) 1 (0.6) 21 (11.7) 0
Hypertension 18 (10.1) 2 (1.1) 16 (8.9) 4 (2.2)
Constipation 10 (5.6) 0 19 (10.6) 0
AEs are presented in overall descending order for the pasireotide LAR
arm, starting with the most frequent
a Two patients randomized to the octreotide LAR treatment arm received
pasireotide LAR in error. These two patients are included in the pasire-
otide LAR treatment arm for the purposes of the safety analysis
Fig. 4 Mean HbA1c over time from core baseline up to month 25
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study, or if the investigator judged that they were receiving
clinical benefit from treatment (irrespective of biochemical
control). Fewer patients in the octreotide LAR arm were
eligible to continue on their randomized therapy in the
extension phase compared with the pasireotide LAR arm
(25.3 versus 42.0 % of patients, respectively). This is in
Table 4 Overall shift in glucose from core baseline to last available value up to month 26










Pasireotide LAR (N = 178)
100 mg/dL 119 (66.9) 35 (19.7) 60 (33.7) 23 (12.9) 1 (0.6)
100 to <126 mg/dL 51 (28.7) 10 (5.6) 18 (10.1) 23 (12.9) 0
126 mg/dL 7 (3.9) 0 3 (1.7) 4 (2.2) 0
Missing 1 (0.6) 1 (0.6) 0 0 0
Total 178 (100.0) 46 (25.8) 81 (45.5) 50 (28.1) 1 (0.6)
Octreotide LAR (N = 180)
100 mg/dL 109 (60.6) 66 (36.7) 40 (22.2) 3 (1.7) 0
100 to <126 mg/dL 54 (30.0) 17 (9.4) 30 (16.7) 7 (3.9) 0
126 mg/dL 17 (9.4)      2 (1.1) 7 (3.9) 8 (4.4) 0
Missing 0 0 0 0 0
Total 180 (100) 85 (47.2) 77 (42.8)    18 (10.0) 0
Shaded boxes represent the patients with a shift in glucose level (mg/dL) that indicates a worse diabetic status at the last reported value compared
with core baseline
Table 5 Overall shift in HbA1c from core baseline to last available value up to month 26




5.7 to 6.5 %
n (%)






Pasireotide LAR (N = 178)
5.7 % 74 (41.6) 17 (9.6) 39 (21.9) 13 (7.3) 4 (2.2) 1 (0.6)
5.7 to 6.5 % 87 (48.9) 4 (2.2) 35 (19.7) 42 (23.6) 6 (3.4) 0
6.5 to 8 % 17 (9.6) 1 (0.6) 2 (1.1) 9 (5.1) 5 (2.8) 0
8 % 0 0 0 0 0 0
Missing 0 0 0 0 0 0
Total 178 (100.0) 22 (12.4) 76 (42.7) 64 (36.0) 15 (8.4) 1 (0.6)
Octreotide LAR (N = 180)
5.7 % 66 (36.7) 31 (17.2) 32 (17.8) 2 (1.1) 0 1 (0.6)
5.7 to 6.5 % 82 (45.6) 7 (3.9) 57 (31.7) 15 (8.3) 2 (1.1) 1 (0.6)
6.5 to 8 % 30 (16.7) 1 (0.6) 13 (7.2) 12 (6.7) 3 (1.7) 1 (0.6)
8 % 2 (1.1)      0 0 1 (0.6) 1 (0.6) 0
Missing 0 0 0 0 0 0
Total 180 (100) 39 (21.7) 102 (56.7)    30 (16.7) 6 (3.3) 3 (1.7)
Shaded boxes represent the patients with a shift in HbA1c level (%) that indicates a worse diabetic status at the last reported value compared with
core baseline
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line with the core study data showing that pasireotide LAR
was significantly superior to octreotide LAR at providing
GH\2.5 lg/L and normal IGF-1 [16], even after
accounting for the fact that four patients could not continue
receiving octreotide LAR in the extension phase as they
entered the study before the protocol amendment was
implemented. As the extension phase was not designed or
powered to compare pasireotide LAR with octreotide LAR,
no conclusions can be drawn regarding the relative efficacy
of these somatostatin analogues over the 25-month treat-
ment period. In addition, because all patients entering the
extension were benefiting from their randomized treatment,
no difference between the treatment arms would be
expected.
At the beginning of the extension phase, 71.6 % of
patients in the pasireotide LAR arm and 56.5 % in the
octreotide LAR arm had GH\2.5 lg/L and IGF-
1 B19 ULN. After 25 months of treatment, the propor-
tions were 60.8 and 52.2 %, respectively. The most com-
mon reason for discontinuation in both treatment arms
during the blinded extension phase was consent with-
drawal; the majority of these patients elected to undergo
pituitary surgery.
During the blinded extension phase, the safety profile of
pasireotide LAR was similar to that of octreotide LAR,
except for the frequency and degree of hyperglycemia. The
safety profiles of pasireotide LAR and octreotide LAR
during the blinded extension phase were similar to those
seen in the 12-month core study. However, although HbA1c
and glucose levels initially increased in the first 3 months
of pasireotide treatment, they then remained stable to
26 months. The administration of anti-diabetic medication,
most commonly metformin, may have contributed to the
lack of further deterioration in glucose homeostasis with
pasireotide LAR; almost half of patients receiving pasire-
otide LAR received an anti-diabetic agent during the
26-month study, while C1 agent was initiated in 40.4 % of
patients who were not receiving medication at baseline. As
changes in the dose of concomitant medications were not
recorded during the 26 months of treatment, further studies
are necessary to determine the effects of anti-diabetic
therapies on the stabilization of HbA1c and glucose levels
during pasireotide treatment. As sst5 receptors are expres-
sed on tissues such as pancreatic islet cells [19], the higher
levels of hyperglycemia observed with pasireotide may be
a result of its higher binding affinity for sst5 compared with
other somatostatin analogues. A recent study in healthy
volunteers has shown that although pasireotide inhibits
insulin secretion and incretin response, with modest sup-
pression of glucagon, it does not affect insulin sensitivity
[20]. After initiation of pasireotide, all patients should be
closely monitored for changes in glucose homeostasis; in
the event of hyperglycemia, prompt intervention is
warranted. Importantly, no new safety signals were iden-
tified in the extension phase that would caution against
long-term use of pasireotide LAR.
In conclusion, pasireotide LAR and octreotide LAR
provide long-term inhibition of GH and IGF-1 in patients
with acromegaly. Therefore, pasireotide LAR is a viable
new treatment option for patients with acromegaly.
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